Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib Plus Fulvestrant
Sponsor: Chinese Academy of Medical Sciences